Trial Profile

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Rituximab (Primary) ; Venetoclax (Primary) ; Cyclophosphamide; Dexamethasone
Indications Waldenstrom's macroglobulinaemia
Focus Therapeutic Use
Acronyms VIWA-1

Most Recent Events

08 Apr 2025 Given protocol has been amended as above-1) Parallel design has been implemented. 2) Status changed to recruiting.
08 Apr 2025 Planned End Date changed from 1 Dec 2032 to 1 Mar 2033.
08 Apr 2025 Planned primary completion date changed from 1 Jan 2028 to 1 Mar 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com